



## Announcement Summary

**Entity name**

MEDIBIO LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Monday May 29, 2023

**The +securities to be quoted are:**

Other

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
MEB	ORDINARY FULLY PAID	163,999,971	30/05/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

MEDIBIO LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type**

ACN

**Registration number**

008130336

**1.3 ASX issuer code**

MEB

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

29/5/2023



Part 2 - Type of Issue

---

**2.1 The +securities to be quoted are:**

Other

**2.2 The +securities to be quoted are:**

Additional +securities in a class that is already quoted on ASX ("existing class")

**2.3c Have these +securities been offered under a +disclosure document or +PDS?**

No

**2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

See Appendix 3B lodged on 15 February 2023 and SPP Prospectus lodged 2 March 2023. There are still further shares to be issued under the SPP shortfall offer and underwriting agreement along with the free attaching options advised under that Appendix 3B.

**2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a +disclosure document or +PDS for the +securities to be quoted



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**Additional +securities to be quoted in an existing class**

**ASX +security code and description**

MEB : ORDINARY FULLY PAID

**Issue date**

30/5/2023

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Issue details

**Number of +securities to be quoted**

163,999,971

**Are the +securities being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?      What is the issue price per +security?**

AUD - Australian Dollar

AUD 0.00150000

**Any other information the entity wishes to provide about the +securities to be quoted**

Shares issued under SPP prospectus.

**The purpose(s) for which the entity is issuing the securities**

Other

**Please provide additional details**

Funds will be used by the Company to progress the Company's FDA application and for general working capital.



## Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
MEB : ORDINARY FULLY PAID	4,314,593,765
MEBOC : OPTION EXPIRING 28-FEB-2024	525,582,972

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
MEBAN : OPTION EXPIRING 06-OCT-2023 EX \$0.012	10,210,500
MEBAD : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	997,811,781
MEBAO : OPTION EXPIRING 08-DEC-2025 EX \$0.011	11,250,000



Part 5 - Other Listing Rule requirements

---

**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

Yes

**5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

23/5/2023

For personal use only